Pfizer’s Talzenna Expansion Fails To Earn FDA Advisory Committee’s Support

The FDA’s independent advisors found Pfizer’s data lacked the precision needed to establish the efficacy of Talzenna in patients with prostate cancer who do not carry HRR mutations.